Chemotherapy-induced Nausea and Vomiting Drugs Market by Therapy and Geography - Forecast and Analysis 2021-2025

1 Executive Summary

2 Market Landscape

• 2.1 Market ecosystem
  • Exhibit 01: Parent market
  • Exhibit 02: Market characteristics

• 2.2 Value chain analysis
  • Exhibit 03: Value chain analysis: Pharmaceuticals Market

3 Market Sizing

• 3.1 Market definition
  • Exhibit 04: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
  • Exhibit 05: Market segments

• 3.3 Market size 2020

• 3.4 Market outlook: Forecast for 2020 - 2025
  • Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
  • Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

4 Five Forces Analysis

• 4.1 Five forces analysis 2020 & 2025

• 4.2 Bargaining power of buyers
  • Exhibit 09: Bargaining power of buyers

• 4.3 Bargaining power of suppliers
  • Exhibit 10: Bargaining power of suppliers

• 4.4 Threat of new entrants
  • Exhibit 11: Threat of new entrants

• 4.5 Threat of substitutes
  • Exhibit 12: Threat of substitutes

• 4.6 Threat of rivalry
  • Exhibit 13: Threat of rivalry

• 4.7 Market condition
  • Exhibit 14: Market condition - Five forces 2020

5 Market Segmentation by Therapy

• 5.1 Market segments
  • Exhibit 15: Therapy - Market share 2020-2025 (%)

• 5.2 Comparison by Therapy
  • Exhibit 16: Comparison by Therapy

• 5.3 Serotonin receptor antagonists - Market size and forecast 2020-2025
  • Exhibit 17: Serotonin receptor antagonists - Market size and forecast 2020-2025 ($ million)
  • Exhibit 18: Serotonin receptor antagonists - Year-over-year growth 2020-2025 (%)

• 5.4 NK1 receptor antagonists - Market size and forecast 2020-2025
  • Exhibit 19: NK1 receptor antagonists - Market size and forecast 2020-2025 ($ million)
  • Exhibit 20: NK1 receptor antagonists - Year-over-year growth 2020-2025 (%)

• 5.5 Others - Market size and forecast 2020-2025
  • Exhibit 21: Others - Market size and forecast 2020-2025 ($ million)
  • Exhibit 22: Others - Year-over-year growth 2020-2025 (%)

• 5.6 Market opportunity by Therapy
  • Exhibit 23: Market opportunity by Therapy

6 Customer landscape

7 Geographic Landscape

• 7.1 Geographic segmentation
  • Exhibit 25: Market share by geography 2020-2025 (%)

• 7.2 Geographic comparison
  • Exhibit 26: Geographic comparison

• 7.3 North America - Market size and forecast 2020-2025
  • Exhibit 27: North America - Market size and forecast 2020-2025 ($ million)
  • Exhibit 28: North America - Year-over-year growth 2020-2025 (%)

• 7.4 Europe - Market size and forecast 2020-2025
  • Exhibit 29: Europe - Market size and forecast 2020-2025 ($ million)
  • Exhibit 30: Europe - Year-over-year growth 2020-2025 (%)

• 7.5 Asia - Market size and forecast 2020-2025
  • Exhibit 31: Asia - Market size and forecast 2020-2025 ($ million)
  • Exhibit 32: Asia - Year-over-year growth 2020-2025 (%)

• 7.6 ROW - Market size and forecast 2020-2025
  • Exhibit 33: ROW - Market size and forecast 2020-2025 ($ million)
  • Exhibit 34: ROW - Year-over-year growth 2020-2025 (%)

• 7.7 Key leading countries
  • Exhibit 35: Key leading countries

• 7.8 Market opportunity by geography
  • Exhibit 36: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges
  • Exhibit 37: Impact of drivers and challenges

• 8.3 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
  • Exhibit 38: Vendor landscape

• 9.3 Landscape disruption
  • Exhibit 39: Landscape disruption
  • Exhibit 40: Industry risks

10 Vendor Analysis

• 10.1 Vendors covered
  • Exhibit 41: Vendors covered

• 10.2 Market positioning of vendors
  • Exhibit 42: Market positioning of vendors

• 10.3 Aurobindo Pharma Ltd.
  • Exhibit 43: Aurobindo Pharma Ltd. - Overview
  • Exhibit 44: Aurobindo Pharma Ltd. - Product and service
  • Exhibit 45: Aurobindo Pharma Ltd. - Key news
  • Exhibit 46: Aurobindo Pharma Ltd. - Key offerings
  • Exhibit 47: Aurobindo Pharma Ltd. - Segment focus

• 10.4 Cipla Inc.
  • Exhibit 48: Cipla Inc. - Overview
  • Exhibit 49: Cipla Inc. - Business segments
  • Exhibit 50: Cipla Inc. - Key news
  • Exhibit 51: Cipla Inc. - Key offerings
  • Exhibit 52: Cipla Inc. - Segment focus

• 10.5 Dr. Reddys Laboratories Ltd.
  • Exhibit 53: Dr. Reddys Laboratories Ltd. - Overview
  • Exhibit 54: Dr. Reddys Laboratories Ltd. - Business segments
  • Exhibit 55: Dr. Reddys Laboratories Ltd. - Key news
  • Exhibit 56: Dr. Reddys Laboratories Ltd. - Key offerings
  • Exhibit 57: Dr. Reddys Laboratories Ltd. - Segment focus

• 10.6 GlaxoSmithKline Plc

• 10.7 Glenmark Pharmaceuticals Ltd.
  • Exhibit 63: Glenmark Pharmaceuticals Ltd. - Overview
  • Exhibit 64: Glenmark Pharmaceuticals Ltd. - Product and service
  • Exhibit 65: Glenmark Pharmaceuticals Ltd. - Key news
  • Exhibit 66: Glenmark Pharmaceuticals Ltd. - Key offerings
  • Exhibit 67: Glenmark Pharmaceuticals Ltd. - Segment focus

• 10.8 Heron Therapeutics Inc.
  • Exhibit 68: Heron Therapeutics Inc. - Overview
  • Exhibit 69: Heron Therapeutics Inc. - Product and service
  • Exhibit 70: Heron Therapeutics Inc.- Key news
  • Exhibit 71: Heron Therapeutics Inc. - Key offerings

• 10.9 Merck and Co. Inc.
  • Exhibit 72: Merck and Co. Inc. - Overview
  • Exhibit 73: Merck and Co. Inc. - Business segments
  • Exhibit 74: Merck & Co. Inc. - Key news
  • Exhibit 75: Merck and Co. Inc. - Key offerings
  • Exhibit 76: Merck and Co. Inc. - Segment focus

• 10.10 Mylan NV
  • Exhibit 77: Mylan NV - Overview
  • Exhibit 78: Mylan NV - Business segments
  • Exhibit 79: Mylan NV - Key news
  • Exhibit 80: Mylan NV - Key offerings
  • Exhibit 81: Mylan NV - Segment focus

• 10.11 Novartis AG
  • Exhibit 82: Novartis AG - Overview
  • Exhibit 83: Novartis AG - Business segments
  • Exhibit 84: Novartis AG - Key news
  • Exhibit 85: Novartis AG - Key offerings
  • Exhibit 86: Novartis AG - Segment focus

• 10.12 Teva Pharmaceutical Industries Ltd.
  • Exhibit 87: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 88: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 89: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 90: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 91: Teva Pharmaceutical Industries Ltd. - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Currency conversion rates for US$
  • Exhibit 92: Currency conversion rates for US$

• 11.3 Research methodology
  • Exhibit 93: Research Methodology
  • Exhibit 94: Validation techniques employed for market sizing
  • Exhibit 95: Information sources

• 11.4 List of abbreviations
  • Exhibit 96: List of abbreviations